Multiomics Market worth $5.70 billion by 2031 - Exclusive Report by MarketsandMarkets™

The multiomics market is projected to grow from $3.18B in 2026 to $5.70B by 2031 (12.3% CAGR), supported by rising demand for integrated omics data and increased use of AI/ML and cloud bioinformatics. North America leads with a 44.2% share in 2025, while spatial omics is the fastest-growing segment (13.8% CAGR) and sequencing holds the largest technology share (37.5% in 2025). The report highlights continued adoption of NGS, mass spectrometry, single-cell and spatial omics, but it is primarily an industry forecast rather than a specific company event.

Analysis

This is more of a validation of a durable tools-and-omics spend cycle than a fresh catalyst. The market is likely over-anchoring on headline TAM growth while underestimating that the monetization pool is concentrated in consumables, service, and workflow lock-in rather than one-time instrument sales; that favors diversified platforms with installed bases and recurring pull-through over pure-play hardware narratives.

Relative winners are the picks-and-shovels names with broad exposure to sample prep, analysis, and proteomics adjacencies: DHR, TMO, and to a lesser extent BRKR and QGEN. TXG has the most torque if spatial adoption keeps compounding, but it also has the highest execution risk because revenue growth must outrun burn and competitive pricing. ILMN remains a sentiment-sensitive name where any share gains in multiomics can be offset by mix pressure elsewhere, so the stock may not re-rate unless management proves durable consumables growth.

The key second-order effect is budget reallocation inside biotech labs: more multiomics spend usually means less elastic purchasing for general consumables and older assay formats, but it can also delay platform standardization and compress margins for vendors competing on instruments. Over 1-3 months, the report itself should have limited price impact; the real test is whether order commentary and backlog convert into higher recurring revenue. Over 6-18 months, the upside only matters if AI-enabled interpretation increases sample throughput and raises attach rates for software/bioinformatics.

Contrarian view: consensus may be too optimistic about TAM conversion. A 12% market CAGR does not automatically translate into above-consensus EPS for the public names, especially if academic and biopharma capex stays disciplined. The thesis is falsified if 2Q/3Q commentary shows flat-to-down instrument orders or if consumables growth fails to inflect despite continued multiomics adoption.

Key Decisions for Investors

• Prefer a basket long in DHR/TMO over TXG/ILMN for the next 3-6 months: better recurring revenue capture, lower execution risk, and less dependence on a single platform win.
• Relative-value idea: long BRKR vs short ILMN into earnings if channel checks confirm continued spatial/proteomics momentum; BRKR has cleaner leverage to the fastest-growing subsegments, while ILMN still needs proof of durable mix improvement.
• Watchlist, not a trade yet: TXG only on evidence of accelerating consumables pull-through and narrowing cash burn; without that, the stock’s upside from market growth is likely offset by dilution/valuation risk.
• Use DHR/TMO as the safer expression of a multiomics capex cycle on any 3-5% pullback; invalidation is a print showing slower reagent/consumables growth or a guidance haircut tied to biotech funding pressure.
• If you want a hedge, pair long tools exposure (DHR or TMO) against a short in the most narrative-sensitive pure-play (ILMN or TXG) to isolate adoption quality rather than beta to the research theme.